536
Participants
Start Date
March 1, 2021
Primary Completion Date
August 18, 2021
Study Completion Date
September 22, 2021
moxidectin (8 mg) / albendazole (400 mg)
Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
ivermectin (200 µg/kg) / albendazole (400 mg)
Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
ivermectin (200 µg/kg)
Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
moxidectin (8 mg)
Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
Public Health Laboratory Ivo de Carneri, Chake Chake
Public Health Laboratory Ivo de Carneri
OTHER
Jennifer Keiser
OTHER